Results 161 to 170 of about 87,925 (315)

Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy [PDF]

, 2002
Stuart L. Goldberg, Ravi A. Madan, Scott D. Rowley, Andrew L. Pecora, Jack W. Hsu, Ramana Tantravahi   +5 more
openalex   +1 more source

Treatment‐Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients

European Journal of Haematology, Volume 114, Issue 5, Page 900-907, May 2025.
ABSTRACT Approximately 40%–60% of patients reaching a stable deep molecular response during TKI treatment will maintain a state of remission after TKI discontinuation, denoted as treatment‐free remission (TFR). Depth of molecular response assessed by BCR::ABL1 digital PCR prior to TKI discontinuation has demonstrated its significance as a reliable ...
C. Kockerols, P. J. M. Valk, P. Hogenbirk, I. Geelen, N. M. A. Blijlevens, J. J. W. M. Janssen, M. Hoogendoorn, S. Kersting, S. K. Klein, L. G. M. Daenen, M. Donker, P. A. W. te Boekhorst, K.‐S. G. Jie, M. Corsten, M. J. Cruijsen, H. Levenga, W. M. Smit, M.‐D. Levin, E. de Jongh, S. de Jonge, A. J. Vlot, M. F. Durian, J. J. Zwaginga, M. Mohlmann, T. J. Wustman, R. Blommers, J. J. Cornelissen, P. E. Westerweel, Collaborating Authors, Y. Bilgin, A.E.C. Broers, R. Brouwer, D.A.R. Castelijn, A.N. de Graaf, A.M.P. Demandt, J. Droogendijk, E.C. de Weerdt, R. van Kampen, E. Libourel, I. Ludwig, M. Oosterveld, R. Oostvogels, J.P. Oudhoff, A. van Rhenen, W. Stevens, J. Swart‐Heikens, D. te Raa, M. van der Klift, D. van Lammeren, R. van Rijn, C. van Rooijen, I.P.G. Verpoorte, D. Willemsen, B.J. Wouters, P.F. Ypma   +54 more
wiley   +1 more source

The potential role of mitochondrial impairment in the pathogenesis of imatinib-induced renal injury

Heliyon, 2019
Imatinib is a tyrosine kinase inhibitor widely administered against chronic myeloid leukemia. On the other hand, drug-induced kidney proximal tubular injury, electrolytes disturbances, and renal failure is a clinical complication associated with imatinib
Ehsan Emadi, Narges Abdoli, Vahid Ghanbarinejad, Hamid Reza Mohammadi, Khadijeh Mousavi Mobarakeh, Negar Azarpira, Zahra Mahboubi, Hossein Niknahad, Reza Heidari   +8 more
doaj  

Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study

Acta Oncologica
Introduction: Metastatic gastrointestinal stromal tumour (GIST) is considered incurable, and life-long treatment with tyrosine kinase inhibitors is recommended.
Ivar Hompland, KJetil Boye, Anne Marit Wiedswang, Andri Papakonstantinou, Bård Røsok, Heikki Joensuu, Øyvind Bruland   +6 more
doaj   +1 more source

Premature hair graying: a multifaceted phenomenon

International Journal of Dermatology, Volume 64, Issue 5, Page 819-829, May 2025.
Abstract Premature hair graying (PHG) is the early loss of natural hair color, influenced by genetic, biological, and environmental factors. This review discusses the significant psychological impacts of PHG and explores its underlying mechanisms, related health conditions, and available treatments.
Deesha D. Desai, Maria Karim, Ambika Nohria, Carli Needle, Anna Brinks, Caitlin A. Kearney, Amy Ridge, Natasha Mesinkovska, Jerry Shapiro, Kristen I. Lo Sicco   +9 more
wiley   +1 more source

Unbiased Drug Target Prediction Reveals Sensitivity to Ferroptosis Inducers, HDAC and RTK Inhibitors in Melanoma Subtypes

International Journal of Dermatology, Volume 64, Issue 5, Page 870-881, May 2025.
Drug target prediction algorithms based on proteogenomic profiling. Abstract Background The utilization of PD1 and CTLA4 inhibitors has revolutionized the treatment of malignant melanoma (MM). However, resistance to targeted and immune‐checkpoint‐based therapies still poses a significant problem.
Indira Pla, Botond L. Szabolcs, Petra Nikolett Péter, Zsuzsanna Ujfaludi, Yonghyo Kim, Peter Horvatovich, Aniel Sanchez, Krzysztof Pawlowski, Elisabet Wieslander, Magdalena Kuras, Jimmy Rodriguez Murillo, Jéssica Guedes, Dorottya M.P. Pál, Anna A. Ascsillán, Lazaro Hiram Betancourt, István Balázs Németh, Jeovanis Gil, Natália Pinto de Almeida, Beáta Szeitz, Leticia Szadai, Viktória Doma, Nicole Woldmar, Áron Bartha, Zoltan Pahi, Tibor Pankotai, Balázs Győrffy, A. Marcell Szasz, Gilberto Domont, Fábio Nogueira, Ho Jeong Kwon, Roger Appelqvist, Sarolta Kárpáti, David Fenyö, Johan Malm, György Marko‐Varga, Lajos V. Kemény   +35 more
wiley   +1 more source

Is there a cloud in the silver lining for imatinib? [PDF]

, 2003
Sarah Paterson, Kevin D. Smith, Tessa L. Holyoake, Heather G. Jørgensen   +3 more
openalex   +1 more source

NPC1 promotes the progression of hepatocellular carcinoma by mediating the accumulation of neutrophils into the tumor microenvironment

FEBS Open Bio, Volume 15, Issue 4, Page 661-673, April 2025.
Compared to normal tissues, NPC1 expression is significantly elevated in hepatocellular carcinoma tissues. Our findings indicate that NPC1 plays a key role in regulating neutrophil recruitment within the tumor, which is a critical factor in the progression of hepatocellular carcinoma and is closely linked to poor patient outcomes.
Songhai Yang, Jiangming Chen, Kun Xie, Fubao Liu   +3 more
wiley   +1 more source

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon

Advanced Therapeutics, Volume 8, Issue 4, April 2025.
Host‐directed therapies (HDTs) represent a transformative approach in infectious disease management by targeting host factors to enhance immune responses and inhibit viral replication. This innovative strategy leverages advanced genomics and gene editing technologies, offering promising avenues for improved patient outcomes and a new horizon in ...
Amol D. Gholap, Pankaj R. Khuspe, Sagar R. Pardeshi, Md Jasim Uddin, Ushasi Das, Navnath T. Hatvate, Satish Rojekar, Prabhanjan Giram, Mohammad Khalid, Yahya E. Choonara, Md. Faiyazuddin   +10 more
wiley   +1 more source

Imatinib mesylate (STI571) therapy for Philadelphia chromosome–positive chronic myelogenous leukemia in blast phase

, 2002
Hagop M. Kantarjian, Jorge E. Cortés, Susan O’Brien, Francis J. Giles, Maher Albitar, Mary Beth Rios, Jianqin Shan, Stefan Faderl, Guillermo Garcia‐Manero, Deborah A. Thomas, Debra Resta, Moshe Talpaz   +11 more
openalex   +1 more source